Searched for: in-biosketch:yes
person:mukhev01
Plasma proteomics reveals shared biologic signatures of acute respiratory failure across etiology and severity in COVID-19 and non-COVID-19 cohorts
Sathe, Neha A; Morrell, Eric D; Stanaway, Ian B; Mabrey, F Linzee; Holton, Sarah E; Mikacenic, Carmen; Anesi, George L; Barnett, Clea R; Brett-Major, David M; Broadhurst, M Jana; Cobb, J Perren; Irwin, Amy; Kumar, Vishakha K; Landsittel, Douglas P; Lee, Richard A; Liebler, Janice M; Lutrick, Karen; Mukherjee, Vikramjit; Postelnicu, Radu; Segal, Leopoldo N; Sevransky, Jonathan E; Srivastava, Avantika; Uyeki, Timothy M; Wyles, David; Evans, Laura E; Bhatraju, Pavan K; Wurfel, Mark M; ,
BACKGROUND:Acute respiratory failure (ARF) is common, exhibits variable outcomes, and arises from diverse causes that incompletely reflect underlying biology. Although the pandemic accelerated molecular investigation of ARF in COVID-19, whether these biologic signals generalize to ARF in hospital populations of varying etiology and severity remains unknown. METHODS:We analyzed aptamer-based plasma proteomics collected within 48 hours of admission across two multihospital studies of varying etiology and severity, including individuals aged ≥14 years with acute viral or respiratory illness, stratified by COVID-19 and non-COVID-19 status (N = 1,096 total across four cohorts). The primary outcome was critical ARF, defined as advanced respiratory support or death by day 7. We identified proteins reproducibly associated with critical ARF in all cohorts, then contextualized protein associations with pathway analysis. Additionally, we developed proteomics-based models for two clinical purposes: predicting critical ARF and identifying heterogeneity of treatment response. RESULTS:We identify 9 proteins associated with critical ARF across cohorts (FDR < 0.05). Seven proteins related to innate immunity, oxidative stress, and barrier disruption are higher in critical ARF, while two proteins linked to immune signaling are lower. Pathway analysis identifies dysregulated inflammatory and fibrotic signaling pathways. Protein-based models improve discrimination of critical ARF beyond clinical variables in non-COVID-19 cohorts. A causal forests model finds elevated IL1RL1 (soluble ST2) is associated with greater benefit from imatinib. CONCLUSIONS:A proteomic signature linked to ARF-related outcomes is reproducible across four cohorts with a breadth of etiologies and severity. The proteins may inform design of novel treatments and enriched clinical trials.
PMCID:13754860
PMID: 43015383
ISSN: 2730-664x
CID: 6075864
Lessons learned on access, equity, and collaboration between public hospital Infectious Diseases leadership and the Health Department during the 2025 Legionnaires'disease outbreak response in New York City [Editorial]
Ratcliffe, Judith; Lamb, Kelsey; Martin, Madhuri; Chan, Justin; McGibbon, Emily; McPherson, Tristan; Episcopia, Briana; Mukherjee, Vikramjit; Wallach, Andrew; Mannheimer, Sharon; Mgbako, Ofole
This commentary presents lessons learned and unique aspects of the public health response of infectious disease physicians, infection prevention and control specialists, and the New York City Health Department to the 2025 Legionella outbreak in Harlem.
PMCID:13760290
PMID: 43032319
ISSN: 2732-494x
CID: 6075949
Lessons learned on access, equity, and collaboration between public hospital Infectious Diseases leadership and the Health Department during the 2025 Legionnaires'disease outbreak response in New York City [Editorial]
Ratcliffe, Judith; Lamb, Kelsey; Martin, Madhuri; Chan, Justin; McGibbon, Emily; McPherson, Tristan; Episcopia, Briana; Mukherjee, Vikramjit; Wallach, Andrew; Mannheimer, Sharon; Mgbako, Ofole
This commentary presents lessons learned and unique aspects of the public health response of infectious disease physicians, infection prevention and control specialists, and the New York City Health Department to the 2025 Legionella outbreak in Harlem.
PMCID:13760290
PMID: 43032319
ISSN: 2732-494x
CID: 6075950
The evolution of biocontainment unit care for high-consequence infectious diseases: progress, lessons learned, and future directions
Chasen, Elizabeth; Biswas, Indrani; Lo Piccolo, Anthony; Leone, Ryan; McGuire, Erin; Mukherjee, Vikramjit; Postelnicu, Radu
Biocontainment units (BCUs) are specialized facilities designed to treat patients with high-consequence infectious diseases (HCIDs) which are pathogens with high mortality rates, limited treatment options, and significant potential for healthcare-associated transmission. Since the opening of the first modern BCU in 1971, these units have evolved from simple isolation environments into advanced centers capable of delivering comprehensive critical care while maintaining rigorous infection control. This evolution has been driven from the lessons learned from past outbreaks of Ebola, Marburg, Middle Eastern Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), among other emerging infectious threats. Four key domains contribute to the care of patients with HCIDs - laboratory capabilities, critical care delivery, healthcare workforce readiness, and safe patient transport. Improvements in diagnostic capabilities have allowed for earlier disease recognition while greater access to routine laboratory tests better inform clinical decision making. Clinical care capabilities now match those seen in intensive care units while maintaining infection control standards. Training of specialized workforce and multidisciplinary staffing models have improved bedside care and operational readiness. Meanwhile, innovations in ground and air transport have enhanced the ability to safely transfer HCID patients to facilities best suited to provide care. This review synthesizes the evolution of BCU capabilities globally, examining advances in critical care, diagnostics, investigational therapeutics, workforce models, and patient transport.
PMCID:13756891
PMID: 43015819
ISSN: 1466-609x
CID: 6075868
The evolution of biocontainment unit care for high-consequence infectious diseases: progress, lessons learned, and future directions
Chasen, Elizabeth; Biswas, Indrani; Lo Piccolo, Anthony; Leone, Ryan; McGuire, Erin; Mukherjee, Vikramjit; Postelnicu, Radu
Biocontainment units (BCUs) are specialized facilities designed to treat patients with high-consequence infectious diseases (HCIDs) which are pathogens with high mortality rates, limited treatment options, and significant potential for healthcare-associated transmission. Since the opening of the first modern BCU in 1971, these units have evolved from simple isolation environments into advanced centers capable of delivering comprehensive critical care while maintaining rigorous infection control. This evolution has been driven from the lessons learned from past outbreaks of Ebola, Marburg, Middle Eastern Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), among other emerging infectious threats. Four key domains contribute to the care of patients with HCIDs - laboratory capabilities, critical care delivery, healthcare workforce readiness, and safe patient transport. Improvements in diagnostic capabilities have allowed for earlier disease recognition while greater access to routine laboratory tests better inform clinical decision making. Clinical care capabilities now match those seen in intensive care units while maintaining infection control standards. Training of specialized workforce and multidisciplinary staffing models have improved bedside care and operational readiness. Meanwhile, innovations in ground and air transport have enhanced the ability to safely transfer HCID patients to facilities best suited to provide care. This review synthesizes the evolution of BCU capabilities globally, examining advances in critical care, diagnostics, investigational therapeutics, workforce models, and patient transport.
PMCID:13756891
PMID: 43015819
ISSN: 1466-609x
CID: 6075869
Plasma proteomics reveals shared biologic signatures of acute respiratory failure across etiology and severity in COVID-19 and non-COVID-19 cohorts
Sathe, Neha A; Morrell, Eric D; Stanaway, Ian B; Mabrey, F Linzee; Holton, Sarah E; Mikacenic, Carmen; Anesi, George L; Barnett, Clea R; Brett-Major, David M; Broadhurst, M Jana; Cobb, J Perren; Irwin, Amy; Kumar, Vishakha K; Landsittel, Douglas P; Lee, Richard A; Liebler, Janice M; Lutrick, Karen; Mukherjee, Vikramjit; Postelnicu, Radu; Segal, Leopoldo N; Sevransky, Jonathan E; Srivastava, Avantika; Uyeki, Timothy M; Wyles, David; Evans, Laura E; Bhatraju, Pavan K; Wurfel, Mark M; ,
BACKGROUND:Acute respiratory failure (ARF) is common, exhibits variable outcomes, and arises from diverse causes that incompletely reflect underlying biology. Although the pandemic accelerated molecular investigation of ARF in COVID-19, whether these biologic signals generalize to ARF in hospital populations of varying etiology and severity remains unknown. METHODS:We analyzed aptamer-based plasma proteomics collected within 48 hours of admission across two multihospital studies of varying etiology and severity, including individuals aged ≥14 years with acute viral or respiratory illness, stratified by COVID-19 and non-COVID-19 status (N = 1,096 total across four cohorts). The primary outcome was critical ARF, defined as advanced respiratory support or death by day 7. We identified proteins reproducibly associated with critical ARF in all cohorts, then contextualized protein associations with pathway analysis. Additionally, we developed proteomics-based models for two clinical purposes: predicting critical ARF and identifying heterogeneity of treatment response. RESULTS:We identify 9 proteins associated with critical ARF across cohorts (FDR < 0.05). Seven proteins related to innate immunity, oxidative stress, and barrier disruption are higher in critical ARF, while two proteins linked to immune signaling are lower. Pathway analysis identifies dysregulated inflammatory and fibrotic signaling pathways. Protein-based models improve discrimination of critical ARF beyond clinical variables in non-COVID-19 cohorts. A causal forests model finds elevated IL1RL1 (soluble ST2) is associated with greater benefit from imatinib. CONCLUSIONS:A proteomic signature linked to ARF-related outcomes is reproducible across four cohorts with a breadth of etiologies and severity. The proteins may inform design of novel treatments and enriched clinical trials.
PMCID:13754860
PMID: 43015383
ISSN: 2730-664x
CID: 6075863
Lessons learned on access, equity, and collaboration between public hospital Infectious Diseases leadership and the Health Department during the 2025 Legionnaires’disease outbreak response in New York City
Ratcliffe, Judith; Lamb, Kelsey; Martin, Madhuri; Chan, Justin; McGibbon, Emily; McPherson, Tristan; Episcopia, Briana; Mukherjee, Vikramjit; Wallach, Andrew; Mannheimer, Sharon; Mgbako, Ofole
This commentary presents lessons learned and unique aspects of the public health response of infectious disease physicians, infection prevention and control specialists, and the New York City Health Department to the 2025 Legionella outbreak in Harlem.
ORIGINAL:7248963
ISSN: 2732-494x
CID: 6074498
Social Media and Crisis Care Principles During Pandemics and Disasters: A Consensus Report From a Subgroup of the Task Force for Mass Critical Care
Persoff, Jason; Devereaux, Asha; Maves, Ryan; Mehta, Anuj B; Burry, Lisa; Chakravarti, Aloke; Levy, Deborah; Feldman, Henry J; Baez, Amado Alejandro; Felzer, Jamie R; Baum, Karyn D; Dries, David J; Mukherjee, Vikramjit; Persson, Drew; Conrad, Taylor S; Hossain, Tanzib; Ghazipura, Marya; Anesi, George L; Ornoff, Doug; Freels, Natalie; Sprung, Charles L; Dichter, Jeffrey R
BACKGROUND:Effective communication and coordination are fundamental determinants of the healthcare system's performance during disasters. Failures in these domains during COVID-19 contributed to disrupted care delivery, strained staff, resource shortages, and adverse patient outcomes. RESEARCH QUESTION/OBJECTIVE:Drawing on pandemic lessons, the Task Force for Mass Critical Care (TFMCC) conducted a comprehensive assessment of peer-reviewed literature, gray sources, and firsthand experience using a modified Delphi process to develop consensus-based suggestions to strengthen communication strategies and operational coordination. STUDY DESIGN AND METHODS/METHODS:Methodological frameworks from the World Health Organization and Guidelines International Network-McMaster Guideline Development Checklist for rapid guidelines were merged to establish a consensus development process, integrating evidence synthesized from the literature with expert opinions. The previously described process used a three-round modified Delphi approach to synthesize published evidence, collect anecdotal evidence, and develop suggestions. RESULTS:A total of 147 evidence statements were evaluated, resulting in 22 suggestions substantiated by other supporting literature and anecdotal experiences. The TFMCC identified transparent, timely, and scientifically grounded public communication with proactive engagement through social media as indispensable for information dissemination and misinformation mitigation. Planning and coordination across federal, state, regional, and hospital systems are critical for effective disaster response, which depends on standardized crisis care frameworks, Medical Operations Coordination Centers, and interoperable health information systems enabling real-time situational awareness. Important findings include community engagement, equitable resource allocation, accessible communication strategies, and processes to avoid restrictive visitation policies that can impede surrogate decision-making. Finally, integrating emergency department expertise into hospital incident command and strengthening the "last mile" of supply-chain distribution are necessary to sustain clinical operations. INTERPRETATION/CONCLUSIONS:Communication and coordination are core operational priorities during disaster response, emphasizing their impact on patient outcomes, system performance, and public trust. Communication and coordination systems require sustained investments in interorganizational relationships and public engagement.
PMID: 42744113
ISSN: 1931-3543
CID: 6072893
Assessing current capabilities and barriers to performing routine laboratory tests on patients with suspected high consequence infectious disease at frontline acute care hospitals
DiLorenzo, Madeline A; Lo Piccolo, Anthony Joseph; Bosk, Jared; Shapiro-Luft, Dina; Biddinger, Paul; Bhadelia, Nahid; Jausurawong, Tani; Sulmonte, Christopher; Mazo, Dana; Phillips, Michael; Jacobson, Jessica L; Mukherjee, Vikramjit; Chan, Justin
INTRODUCTION/BACKGROUND:Patients with a suspected high-consequence infectious disease (HCID), such as Ebola virus disease, may require routine laboratory testing to guide management. We assessed the capabilities of frontline hospitals and the barriers they face performing laboratory testing for patients with a suspected HCID. METHODS:A one-time confidential REDCap survey querying capabilities to safely perform laboratory tests that the Centers for Disease Control and Prevention considers critical for patients with a suspected HCID was sent to 95 institutions in Baltimore, MD, Boston, MA, New York City, NY, and Washington, DC, from January to May 2025. RESULTS:Fifty (53%) institutions responded, mostly teaching hospitals (96%), with 24% reporting prior experience evaluating a patient with suspected Ebola virus disease. While many hospitals could perform on-site blood gas (70%), hemoglobin/hematocrit (68%), and lactate (68%) tests on a suspected HCID patient, fewer could safely perform a chemistry panel (64%), a urinalysis (60%), a complete blood count with differential (56%), and a malaria rapid diagnostic test (RDT) (48%) on a suspected HCID patient. The five tests respondents most often considered extremely or very important were hemoglobin/hematocrit (91%), chemistry panel (90%), CBC with differential and platelet count (89%), malaria RDT (88%), and blood gas (88%). Reported barriers to performing routine laboratory testing included issues related to patient and staff safety, infection control, lack of appropriate space, and funding. CONCLUSIONS:Our survey identified several barriers to implementing safe laboratory testing. The inability to conduct these laboratory tests may result in delays in care when an HCID is suspected.
PMID: 42204991
ISSN: 1559-6834
CID: 6070378
From Ebola to H5N1: Strengthening the U.S. Special Pathogen Response System
Lo Piccolo, Anthony Joseph; McGuire, Erin; Postelnicu, Radu; Jano, Kathryn; Leone, Ryan; Jacobson, Eliana; Vasa, Angela; Schwedhelm, Michelle; Mukherjee, Vikramjit
The National Special Pathogens System (NSPS) stratifies U.S. healthcare facilities by their readiness level to care for patients with high-consequence infectious diseases (HCIDs). While NSPS Level 1 and 2 facilities possess advanced biocontainment capabilities to care for patients for the duration of their illness, most U.S. hospitals fall under a NSPS Level 3 or 4 designation, with limited resources to manage patients with a suspected or confirmed HCID. However, emerging zoonotic threats like H5N1 underscore the need to bolster HCID preparedness across all NSPS Levels. Beginning in March 2024, the U.S. H5N1 outbreak has primarily impacted wild bird flocks, poultry, and cattle, along with some human infections. The continuation of this outbreak in wild and domesticated animals increases the likelihood of further human spillover and eventual viral evolution in human hosts. At the frontlines, rural farming communities are likely to be most affected, with potential outbreaks exacerbated by a lack of accessible NSPS Level 1, 2, or 3 facilities in these regions. Thus, strengthening the HCID preparedness of local NSPS Level 4 facilities is critical to preventing transmission, minimizing societal disruption, protecting communities and the healthcare workforce, along with ensuring an equitable, coordinated response to future emerging infectious disease threats. This manuscript explores the financial, societal and health system impacts of HCID outbreaks to delineate the necessity of strengthening the preparedness of NSPS Level 4 facilities.
PMCID:13297867
PMID: 42346166
ISSN: 2673-3986
CID: 6056102